| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4217521 | Thoracic Surgery Clinics | 2007 | 7 Pages |
Abstract
Results of trials reported in the last four years have convincingly demonstrated a role for adjuvant or postoperative chemotherapy in the management of good performance status patients after a complete resection of their stages II and IIIA non-small cell lung cancer. The role of chemotherapy after surgery of stage I disease, however, remains a subject of debate. This article reviews the limited data that pertain to this approach in early stage disease and set the stage for future trials in this population of patients.
Related Topics
Health Sciences
Medicine and Dentistry
Pulmonary and Respiratory Medicine
Authors
Eric MD, FRCSC,